Repository logo

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era.

Accepted version



Change log


Barker, Roger A 
Parmar, Malin 
Studer, Lorenz 
Takahashi, Jun 


Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.



Adult, Aged, Clinical Trials as Topic, Dopaminergic Neurons, Humans, Middle Aged, Parkinson Disease, Stem Cell Transplantation

Journal Title

Cell Stem Cell

Conference Name

Journal ISSN


Volume Title



Elsevier BV
Medical Research Council (MC_PC_12009)
European Commission (602278)
We would like to thank Jeanne Loring and her team for contributing to the discussion and Table 1, Ulrika Blank Savukinas for illustration help, as well as all the funding agencies that have supported work within GForce-PD over the last few years including the EU (TRANSEURO and NeuroStemcellRepair no. 602278); the UK RMP Pluripotent stem cell hub; Cure Parkinson’s Trust; Rosetrees Trust; MRC-WT funding of the Cambridge Stem Cell Institute and the NIHR funding of the Biomedical Research Centre in Cambridge; The Swedish Research Council; The Swedish Brain foundation and the Swedish Parkinson Foundation; New York State Stem Cell Science (NYSTEM), and a grant from the Network Program for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development. MP is a New York Stem Cell Foundation Robertson Investigator.